Pediatric AMKL Supplementary Table: Supplementary Table S1: Characteristics of eight AMKL patients with t(1;22)(p13;q13) Patient Age (y) Sex Karyotype Therapy Outcome #1 0.12 m 46,XY,t(1;22)(p13;q13)[8] AML-BFM 98 Death in CCR after MUD HSCT #2 0.24 f 46,XX,t(1;22)(p13;q13)[13] AML-BFM 04 CCR after MUD HSCT in NR #3 0.59 f no karyotype, t(1;22)(p13;q13) in FISH AML-BFM 04 Early Death #4 0.30 f 46,XX,inv(7)(q21q33)[18]; 46,idem,t(1;22)(p31;q12)[2] AML-BFM 04 CCR after MRD HSCT in NR #5 1.19 m 49,XY,t(1;22)(p13;q13),+2,der(2)(p),+8,+19[cp11] AML-BFM 04 CR #6 1.52 f no karyotype, t(1;22)(p13;q13) in FISH AML-BFM 04 Early Death #7 0.25 m 50~55,t(1;22)(p13;q13),inc AML-BFM 98 CR #8 6.26 m 68~69,XXYY,der(1)t(1;22)(p13;q13)
